Top Markets
Coin of the day
DelMar Pharmaceuticals, Inc. DelMar Pharmaceuticals, Inc.

DelMar Pharmaceuticals, Inc.

DMPWW
Peringkat dalam Saham #42376
Kintara Therapeutics, Inc., previously known as DelMar Pharmaceuticals, Inc.... Kintara Therapeutics, Inc., previously known as DelMar Pharmaceuticals, Inc. until its rebranding in August 2020, operates as a clinical-stage pharmaceutical firm. Headquartered in San Diego, California, and established in 2009, the company is committed to advancing and bringing to market anti-cancer treatments for patients. Its development pipeline includes two advanced therapeutic candidates. One is VAL-083, a DNA-targeting agent poised for Phase III trials, designed to combat various drug-resistant solid tumors such as glioblastoma multiforme, ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma. The other is REM-001, a late-stage photodynamic therapy intended for conditions like cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and addressing access graft failure in hemodialysis patients. Kintara Therapeutics also maintains a strategic alliance with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. for the manufacturing and commercialization of VAL-083 within the Chinese market.
Harga Saham
$0.005
Terakhir disinkronkan: 2024-06-20
Kapitalisasi Pasar
$1.74K
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan DelMar Pharmaceuticals, Inc. (DMPWW)

Kategori

Rasio P/S untuk DelMar Pharmaceuticals, Inc. (DMPWW)
Rasio P/S per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari DelMar Pharmaceuticals, Inc., rasio P/S saat ini (TTM) adalah 0. Pada akhir 2026, rasio P/S perusahaan adalah 0.
Riwayat rasio P/S untuk DelMar Pharmaceuticals, Inc. dari 2026 hingga 2026
Rasio P/S pada akhir setiap tahun
Tahun Rasio P/S Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Rasio P/S untuk perusahaan sejenis atau pesaing
Perusahaan Rasio P/S Perbedaan Rasio P/S Negara
9.88 -
US
10.30 -
NL
- -
CH
4.98 -
BE
- -
KR